Literature DB >> 25740995

Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

David R McGivern1, Takahiro Masaki2, William Lovell2, Chris Hamlett3, Susanne Saalau-Bethell3, Brent Graham3.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) NS3 is a multifunctional protein composed of a protease domain and a helicase domain linked by a flexible linker. Protease activity is required to generate viral nonstructural (NS) proteins involved in RNA replication. Helicase activity is required for RNA replication, and genetic evidence implicates the helicase domain in virus assembly. Binding of protease inhibitors (PIs) to the protease active site blocks NS3-dependent polyprotein processing but might impact other steps of the virus life cycle. Kinetic analyses of antiviral suppression of cell culture-infectious genotype 1a strain H77S.3 were performed using assays that measure different readouts of the viral life cycle. In addition to the active-site PI telaprevir, we examined an allosteric protease-helicase inhibitor (APHI) that binds a site in the interdomain interface. By measuring nucleotide incorporation into HCV genomes, we found that telaprevir inhibits RNA synthesis as early as 12 h at high but clinically relevant concentrations. Immunoblot analyses showed that NS5B abundance was not reduced until after 12 h, suggesting that telaprevir exerts a direct effect on RNA synthesis. In contrast, the APHI could partially inhibit RNA synthesis, suggesting that the allosteric site is not always available during RNA synthesis. The APHI and active-site PI were both able to block virus assembly soon (<12 h) after drug treatment, suggesting that they rapidly engage with and block a pool of NS3 involved in assembly. In conclusion, PIs and APHIs can block NS3 functions in RNA synthesis and virus assembly, in addition to inhibiting polyprotein processing. IMPORTANCE: The NS3/4A protease of hepatitis C virus (HCV) is an important antiviral target. Currently, three PIs have been approved for therapy of chronic hepatitis C, and several others are in development. NS3-dependent cleavage of the HCV polyprotein is required to generate the mature nonstructural proteins that form the viral replicase. Inhibition of protease activity can block RNA replication by preventing expression of mature replicase components. Like many viral proteins, NS3 is multifunctional, but how PIs affect stages of the HCV life cycle beyond polyprotein processing has not been well studied. Using cell-based assays, we show here that PIs can directly inhibit viral RNA synthesis and also block a late stage in virus assembly/maturation at clinically relevant concentrations.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740995      PMCID: PMC4442512          DOI: 10.1128/JVI.03188-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.

Authors:  David N Frick; Ryan S Rypma; Angela M I Lam; Baohua Gu
Journal:  J Biol Chem       Date:  2003-10-29       Impact factor: 5.157

2.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

3.  Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes.

Authors:  Kui Li; Zihong Chen; Nobuyuki Kato; Michael Gale; Stanley M Lemon
Journal:  J Biol Chem       Date:  2005-02-28       Impact factor: 5.157

4.  Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells.

Authors:  K A Morgenstern; J A Landro; K Hsiao; C Lin; Y Gu; M S Su; J A Thomson
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase.

Authors:  Angela M I Lam; David N Frick
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis.

Authors:  Frank Scholle; Kui Li; Francis Bodola; Masanori Ikeda; Bruce A Luxon; Stanley M Lemon
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein.

Authors:  P Neddermann; A Clementi; R De Francesco
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.

Authors:  Xiao-Dong Li; Lijun Sun; Rashu B Seth; Gabriel Pineda; Zhijian J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

10.  Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.

Authors:  Carola Berger; Inés Romero-Brey; Danijela Radujkovic; Raphael Terreux; Margarita Zayas; David Paul; Christian Harak; Simone Hoppe; Min Gao; Francois Penin; Volker Lohmann; Ralf Bartenschlager
Journal:  Gastroenterology       Date:  2014-07-18       Impact factor: 22.682

View more
  19 in total

1.  Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.

Authors:  Jinhong Ren; Isabel Ojeda; Maulik Patel; Michael E Johnson; Hyun Lee
Journal:  Bioorg Med Chem Lett       Date:  2019-06-08       Impact factor: 2.823

Review 2.  Modelling hepatitis C therapy--predicting effects of treatment.

Authors:  Alan S Perelson; Jeremie Guedj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

3.  Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus.

Authors:  Kazuhisa Murai; Tetsuro Shimakami; Christoph Welsch; Takayoshi Shirasaki; Fanwei Liu; Juria Kitabayashi; Shiho Tanaka; Masaya Funaki; Hitoshi Omura; Tomoki Nishikawa; Ariunaa Sumiyadorj; Masao Honda; Shuichi Kaneko
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.

Authors:  Nadezhda T Doncheva; Francisco S Domingues; David R McGivern; Tetsuro Shimakami; Stefan Zeuzem; Thomas Lengauer; Christian M Lange; Mario Albrecht; Christoph Welsch
Journal:  J Mol Biol       Date:  2019-04-30       Impact factor: 5.469

5.  Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.

Authors:  Georg Dultz; Tetsuro Shimakami; Markus Schneider; Kazuhisa Murai; Daisuke Yamane; Antoine Marion; Tobias M Zeitler; Claudia Stross; Christian Grimm; Rebecca M Richter; Katrin Bäumer; MinKyung Yi; Ricardo M Biondi; Stefan Zeuzem; Robert Tampé; Iris Antes; Christian M Lange; Christoph Welsch
Journal:  J Biol Chem       Date:  2020-08-03       Impact factor: 5.157

6.  Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Authors:  Stéphanie B N Serre; Sanne B Jensen; Lubna Ghanem; Daryl G Humes; Santseharay Ramirez; Yi-Ping Li; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

7.  Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.

Authors:  Theodore J Cory; Ying Mu; Yuqing Gong; Sunitha Kodidela; Santosh Kumar
Journal:  Expert Opin Pharmacother       Date:  2018-04-10       Impact factor: 3.889

Review 8.  Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.

Authors:  Alan S Perelson; Ruian Ke
Journal:  Clin Pharmacol Ther       Date:  2021-03-08       Impact factor: 6.875

9.  Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.

Authors:  Sungjin Lee; Kee Dong Yoon; Myungeun Lee; Yoojin Cho; Gahee Choi; Hongje Jang; BeomSeok Kim; Da-Hee Jung; Jin-Gyo Oh; Geon-Woo Kim; Jong-Won Oh; Yong-Joo Jeong; Ho Jeong Kwon; Soo Kyung Bae; Dal-Hee Min; Marc P Windisch; Tae-Hwe Heo; Choongho Lee
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

10.  Evaluation of antiviral drug synergy in an infectious HCV system.

Authors:  Billy Lin; Shanshan He; Hyung Joon Yim; T Jake Liang; Zongyi Hu
Journal:  Antivir Ther       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.